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Highlights 
 
 Unclear if tissue diagnosis in poor PS lung cancer patients alters outcomes 
 Tissue diagnosis did not affect treatment or survival in most PS 3 or 4 patients 
 Those receiving treatment requiring tissue diagnosis had improved survival 
 Aids decision whether to pursue tissue in PS 3 or 4 patients. 
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MicroAbstract 
Currently there is controversy surrounding whether a tissue diagnosis in patients with 
lung cancer and poor performance status (PS) affects subsequent management and 
survival. The findings from this study suggest that the majority of patients with PS 3 
or 4 undergo a diagnostic procedure which does not affect further treatment or affect 
survival. However, those poor PS patients who do have treatment requiring tissue 
diagnosis have improved survival, the majority of whom have small cell lung cancer. 
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Abstract 
Introduction 
25% of patients with lung cancer have performance status 3 or 4. A pragmatic 
approach to investigative procedures is often adopted based on the risks and benefits 
in these patients and whether tissue diagnosis is necessary for anticipated future 
treatment. This cohort study investigated factors influencing a clinician’s decision to 
pursue a tissue diagnosis in patients with lung cancer and performance status 3 and 4 
and to examine the association of tissue diagnosis with subsequent management and 
survival. 
 
Methods  
All patients with lung cancer diagnosed in North Glasgow from 2009 to 2012 were 
prospectively recorded in a registry. We investigated the relationships between 
achieving a tissue diagnosis, treatment and survival.  
 
Results 
Of 2493 patients diagnosed with lung cancer, 490 patients (20%) were PS 3 and 122 
patients (5%) were PS 4. Tissue diagnosis was attempted in 60% and 35% patients 
with PS 3 and PS 4 respectively. Younger age, better performance status and having 
stage 4 disease were independently associated with a diagnostic procedure being 
performed.  
 
Only 5% of patients with poor performance status received treatment conventionally 
requiring a tissue diagnosis. Age, stage and performance status were independent 
predictors of mortality. Achieving a tissue diagnosis was not associated with 
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mortality. Receiving treatment requiring tissue diagnosis is associated with survival 
benefit. 
 
Conclusions 
The majority of patients with poor fitness undergo a diagnostic procedure which does 
not influence further treatment or affect survival. However, the cohort of patients who 
do undergo therapy determined by tissue diagnosis have improved survival.  
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1. Introduction 
Lung cancer is still the most common cause of cancer death in the UK,(1) and whilst 
the overall age-standardised incidence of lung cancer in the UK is slowly 
decreasing,(2) the age-standardised incidence of lung cancer in women over the age 
of 75 is increasing. Patients over 75 accounted for around half of all patients 
diagnosed with lung cancer in 2009 to 2011, and with the elderly population 
continuing to grow due to improved life expectancy, this pattern is likely to 
continue.(3) 
 
The diagnosis and management of lung cancer in elderly and less physically fit 
patients is particularly challenging. Procedures that are considered safe and minimally 
invasive in well individuals are often less well tolerated and may have increased 
potential risks in patients with poor performance status. In addition, complex 
comorbidities affect treatment decisions (4) along with a lack of clear evidence for 
benefit versus risk of palliative therapies, such as chemotherapy, in this population. 
 
In general, tissue confirmation is usually required for radical treatment (surgery or 
radical radiotherapy) and is mandatory for chemotherapy including targeted therapy, 
and immunotherapy. The NICE guidelines published in 2011 suggest aiming for 
histological confirmation in 80% of patients.(5) National Lung Cancer Standards 
published by NHS Quality Improvement Scotland in 2008 include a minimal standard 
rate of histological confirmation of 75%.(6) These targets were set for all patients, 
irrespective of fitness. The National Lung Cancer Audit (NLCA) presented the 
national figures for tissue diagnosis in the UK in 2013. The median tissue diagnosis 
rate was 75%.(7) Indeed, in patients with PS 0 or 1 or younger patients with PS 2 
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there may be a survival advantage in confirming tissue diagnosis.(8)   Tissue 
diagnosis is also required for newer and potentially less toxic treatments such as 
EGFR TKIs, ALK inhibitors and immunotherapy, but at present these treatments are 
only suitable for a small minority of patients.   
 
In the NLCA cohort between 2004 and 2010, median tissue diagnosis rates for 
patients with performance status 3 and 4 was 55% and 40% respectively.(8) This 
implies that clinicians deemed that a pragmatic approach was appropriate in those 
patients where tissue diagnosis was not performed: either they were not fit to undergo 
a diagnostic procedure, that obtaining a tissue diagnosis would have no significant 
bearing on the future management of the individual or that the radiological findings 
were sufficient to make a diagnosis. Alternatively, the patient may elect not to have a 
diagnostic procedure.  
 
The aims of this study were to investigate factors that influence a clinician’s decision 
to pursue a tissue diagnosis in patients with lung cancer presenting with performance 
status 3 and 4 and to examine the relationship of tissue diagnosis on subsequent 
management and survival. 
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2. Methods 
2.1 Data collection 
Data for all patients diagnosed with lung cancer in North Glasgow between January 
2009 and December 2012 were collected prospectively at multidisciplinary team 
(MDT) meetings across 3 sites (Gartnavel General Hospital, Glasgow Royal 
Infirmary and Stobhill Hospital) and collated to examine lung cancer demographics 
for the National Lung Cancer Audit and Information Service Division Scotland. This 
database has approval from the West of Scotland Regional Ethics Committee. The 
three hospitals serve a local population for the Northern half of the NHS Greater 
Glasgow and Clyde Health Board which comprises approximately 600,000 patients.  
 
Patient characteristics collected for the MDT included age, sex, tissue diagnosis, 
investigations, performance status (PS, World Health organisation classification), 
stage of cancer (I to IV consistent with the International Association for the Study of 
Lung Cancer 7th edition) and treatment. Date of diagnosis was the MDT meeting date, 
which is conducted on a weekly basis for all incident lung cancers that week. Time to 
survival was measured from the date of diagnosis to date of all-cause mortality. In 
general, performance status was assessed by the clinician reviewing the patient prior 
to the MDT. Patients were allocated a deprivation quintile as a marker for socio-
economic status according to the Scottish Index of Multiple Deprivation (SIMD), 
which was identified based on the patient’s full postcode.(9)  The SIMD combines 38 
indicators across 7 domains which are income, employment, health, education, skills 
and training, housing, geographic access and crime.  
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2.2 Statistical analysis 
Summary statistics were described as number of subjects and percentages for all 
categorical variables. Logistic regression analyses were performed to estimate the 
odds ratio and 95% confidence intervals (95%CI) for factors related to having a tissue 
diagnosis.  Cox Proportional hazards regression was performed to estimate hazard 
ratios and 95%CI for factors associated with all-cause mortality.  For both logistic 
regression and cox regression, initial univariate analysis was performed using relevant 
variables and those with an association yielding a p-value of less than 0.1 were put 
into the final models. SPSS version 22.0 was used for analysis and the graphs 
generated using GraphPad Prism 6.0. 
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3. Results 
There were 2493 patients diagnosed with lung cancer between 2009 and 2012. The 
mean age was 71 with an even gender split (male sex 49%; Table 1). The majority of 
patients had stage 3B or 4 lung cancer at diagnosis (64%). The median follow up 
period was 43 months (minimum 17, maximum 70) and 98% of patients were 
followed up to death or 2 years. 
 
Performance status was documented in 93% of patients. Pathological tissue diagnosis 
was confirmed in 96% of PS 0 and 1 patients and 80% in PS 2. There were 490 
patients (20%) with PS 3 and 122 patients (5%) with PS 4 (Table 2). These less fit 
patients were older (all patients mean age 71; PS 3 and 4 mean age 76) and had a 
female preponderance (all patient male sex 49%; PS 3 and 4 45%). Tissue diagnosis 
was attempted in 60% and 35% and was successful in 50% and 27% of patients with 
PS 3 and PS 4 respectively. 62% of PS3 and 83% of PS4 patients had stage 4 lung 
cancer. 9% of PS3 and 7% of PS 4 patients had more than one procedure. 
 
Logistic regression was performed to assess whether specific patient characteristics 
influenced clinicians’ decisions regarding attempting tissue diagnosis (Table 3). As 
expected, younger age and better performance status were independently associated 
with a diagnostic procedure being performed. Additionally, patients with either stage 
1 or stage 4 disease were more likely to undergo a diagnostic procedure than those 
with stage 2 or 3.  
 
Subsequent treatment of lung cancer is shown in Table 2 and Figure 1. 8 (2%) patients 
of performance status 3 underwent radical radiotherapy, 25 (5%) had chemotherapy, 
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118 (24%) had palliative radiotherapy, 339 (69%) had best supportive care. Thus, 
only 7% of patients with PS3 received treatment that conventionally requires a tissue 
diagnosis. No patients of performance status 4 underwent radical radiotherapy or 
chemotherapy, 6 (5%) had palliative radiotherapy and 116 (95%) had best supportive 
care.  
 
As anticipated, age, performance status and stage were independent predictors of 
mortality (Table 4). Although having a tissue diagnosis was not was associated with 
improved survival (hazard ratio 1.08 [95% CI 0.91-1.26], p=0.38; Table 4, Figure 2A) 
receiving treatment requiring a tissue diagnosis was (HR 0.63 [95% CI 0.44-0.92], 
p=0.01; median 86 days vs 38 days; Figure 2B). The majority of these patients had 
small cell lung cancer (Table 5). 
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4. Discussion 
Almost all randomised controlled trials evaluating therapy in patients with lung 
cancer recruit patients of good performance status (PS).(10) However, a significant 
minority of patients in clinical practice are of PS 3 and 4. In the UK Lung Cancer 
audit between 2004 and 2010, patients of PS 3 and 4 accounted for 24% of patients at 
presentation with lung cancer, where PS was recorded.(8)  
 
In a cohort of patients with a poor PS, we have looked at which patients undergo a 
diagnostic procedure and its influence on treatment and mortality.  In our large cohort, 
25% of patients had poor PS. 60% and 35% of patients with PS 3 and 4 underwent a 
diagnostic procedure respectively.  We found that younger age and better performance 
status were independently associated with the performance of a diagnostic procedure, 
but not sex or socio-economic status. In a study of patients diagnosed with lung 
cancer in England and Wales from 2004 to 2010, younger age, better performance 
status, stage, comorbidity and deprivation all affected pathological confirmation.(8) 
Interestingly, stage 1 and stage 4 patients were more likely to have a diagnostic 
procedure than those with stage 2 and 3 at presentation. It is likely that that those with 
early stage lung cancer are more likely to have a diagnostic procedure as an 
alternative diagnosis is more likely than in those with more advanced disease. 
Furthermore, these patients are more likely to be eligible for radical treatment. Those 
with stage 4 cancer are more likely to have a diagnostic procedure as their extent of 
disease will make tissue diagnosis easier. 
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The recommendations of the 2011 NICE guideline development group and the 2008 
Healthcare Improvement Scotland National Lung Cancer Standards were that trusts 
increase their tissue diagnosis rates towards the national average of 75% for all 
patients, irrespective of general fitness. It is clear that this will differ depending on 
PS. It may be more appropriate to suggest the tissue diagnosis rates are higher than 
90% in patients with PS 0 to 2. This would leave clinicians free to make pragmatic 
decisions on whether to perform invasive, unpleasant and potentially hazardous tests 
depending on the need to confirm the diagnosis or direct treatment. Traditionally 
respiratory physicians perform the tests necessary to confirm diagnosis in patients 
with lung cancer, prior to review by the oncologists who then decide on fitness for 
treatment after a multidisciplinary meeting. A change in this approach might be 
required to assess fitness for treatment requiring a tissue diagnosis prior to performing 
any diagnostic test. 
 
There are a number of reasons for choosing to obtain a tissue diagnosis in patients 
with lung cancer. Firstly it is used to confirm the diagnosis. However, two-thirds of 
patients of poor performance status have radiologically confirmed stage 4 lung cancer 
and thus pathological confirmation is less likely to be essential to secure a diagnosis. 
In some patients, tissue diagnosis is obtained as part of a therapeutic procedure to 
improve symptoms, such as aspiration of a pleural effusion.  Pleural aspiration is less 
invasive than bronchoscopy or lung biopsy.  The higher proportional rate of pleural 
aspirate as a diagnostic procedure in our PS 3 and 4 patients may reflect this (Table 
2).  
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An alternative reason for performing a diagnostic procedure is to direct therapy. 
Historically, patients with PS 3 and 4 would not be considered for systemic treatment. 
The risks of side effects and toxicity were thought to outweigh the benefits. However, 
there is evidence that palliative chemotherapy in patients with Karnofsky PS 60-70 
(equivalent to WHO PS 2 or 3) may derive symptomatic benefit, even without 
improving survival.(13) In addition, new, molecular directed therapies such as 
tyrosine kinase inhibitors (TKIs) and ALK inhibitors are better tolerated than standard 
chemotherapy regimens and have been shown in Japan to improve survival even in 
unfit patients.(14) Indeed, performance status is influenced by cancer as well as age 
and comorbidity. Acute decline in performance status due to cancer activity may be 
improved with systemic therapy, although there is limited evidence that chemotherapy 
in patients of PS3 and 4 is beneficial. A previous reported series in small cell lung 
cancer show very poor survival even with systemic therapy.(15) In this study, 27% of 
patients with PS 4 had a tissue diagnosis. However, none of these patients received 
treatment that required confirmation of tissue type ie radical radiotherapy or 
chemotherapy. Furthermore, their median survival was 12 days.   
 
Despite 50% of PS3 patients having tissue diagnosis confirmed, in only 13% of these 
patients did this influence further treatment. Overall, there was no difference in 
mortality between patients with and without a tissue diagnosis, even after adjusting 
for other factors which may affect survival including age and stage. However, 
receiving treatment requiring tissue confirmation was independently associated with 
survival, independent of age and stage. This subset was younger, had a female 
predominance and more likely to have a diagnosis of small cell lung cancer. These 
findings back up the traditional opinion that patients should undergo a diagnostic 
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procedure as the pathology may confirm small cell lung cancer which is more likely 
to have a favourable response to chemotherapy. This is likely to extend to non-small 
cell lung cancers that are EGFR or ALK positive and thus amenable to TKIs and ALK 
inhibitors that are better tolerated with a lesser side-effect profile, but at present this 
only represents a small minority of patients. 
 
We recognise that rates of treatment with chemotherapy in patients with PS 3 and 4 
vary between centres, and this may be higher in some specialist centres treating highly 
selected patients in comparison to our unselected cohort. All patients in this study 
were discussed at a MDT in the presence of three consultant lung cancer oncologists 
and, along with performance status, other factors such as co-morbidities, patient’s 
wishes, expectation and deprivation level may have been relevant in the decision not 
to give systemic treatment. 
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5. Limitations 
This cohort of patients is from the North Glasgow area. While a significant proportion 
of the patients are of lower socioeconomic status, there is a reasonable distribution. 
This distribution will be similar to many other industrial towns and cities with high 
prevalence of cigarette smoking and similar rates of lung cancer, and thus the findings 
are relevant and applicable to other areas of the UK and overseas. 
 
It is possible that the patients who underwent treatment directed by their tissue 
diagnosis had been misclassified as PS3. While a useful measure of general fitness, 
this scale is subjective. Indeed in a study of 100 consecutive cancer patients from 
Denmark, overall there was only moderate agreement between three oncologists 
recording performance status (overall Kappa 0.55).(18) However, in our cohort, 
performance status is independently associated with mortality and thus likely to be 
accurate in the majority of cases. 
 
6. Conclusion 
Thus in this cohort, many patients of performance status 4 undergo a diagnostic 
procedure which does not influence further treatment or affect survival. However, 
some patients of performance status 3 received treatment determined by tissue 
diagnosis and this is associated with improved survival. Therefore, patients with 
performance status 3 who would be considered for chemotherapy, including 
biological or targeted therapy, should be offered a tissue diagnosis. 
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7. Clinical Practice Points 
 
 It is currently not known whether a tissue diagnosis in patients with lung 
cancer and poor performance status (PS) affects subsequent management and 
survival.  
 The majority of patients with PS 3 or 4 underwent a diagnostic procedure 
which did not affect further treatment or affect survival.  
 However, those patients who did have treatment requiring tissue diagnosis had 
improved survival – the majority of these had small cell lung cancer. 
 This manuscript will aid clinicians in making decisions regarding whether or 
not to obtain histological confirmation in the 25% of patients who are 
performance status 3 or 4. 
 
.
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9. Tables 
 
Table 1: Patient characteristics  
 
All data presented as n (%) except mean age (standard deviation) 
* 1 patient not staged due concurrent pulmonary inflammatory disease process. SD: 
standard deviation. 
 Entire 
cohort 
Performance status 3 Performance status 4 
  Tissue 
diagnosis 
attempted 
Tissue 
diagnosis not 
attempted 
Tissue 
diagnosis 
attempted 
Tissue 
diagnosis  not 
attempted 
N  2493 295 (60)  195 (40) 43 (35) 79 (65) 
Male sex  1232 (49) 133 (45) 84 (43) 22 (51) 38 (48) 
Mean age (SD) 71 (10) 73 (9) 79 (8) 74 (8) 78 (10) 
Stage      
1 399 (16) 19 (7) 24 (12) 2 (3) 0 
2 167 (7) 9 (3) 21 (11) 2 (3) 0 
3 660 (26) 80 (27) 34 (17) 8 (10) 9 (21) 
4 1266 (51) 187 (63) 116 (60) 67 (85) 34 (79) 
Scottish Index of Multiple 
Deprivation 
     
Most deprived 1  1352 (54) 179 (61) 111 (57) 26 (61) 44 (55) 
2 468 (19) 54 (18) 38 (20) 7 (16) 19 (24) 
3 246 (10) 26 (9) 15 (8) 2 (5) 4 (5) 
4 206 (8) 18 (6) 16 (8) 3 (7) 3 (4) 
Least deprived 5  221 (9) 18 (6) 15 (8) 5 (12) 9 (11) 
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Table 2: Survival, tissue typing and treatment 
All data presented as n (%) except median survival (interquartile range) 
 
IQR: interquartile range; EBUS: endobronchial ultrasound; SCLC: small cell lung 
cancer; NSCLC: non small cell lung cancer; XRT: radiotherapy.
 All Performance 
status 3 
 
Performance 
status 4 
 
n 2493 490 122 
Dead 2195 (88) 481 (98) 122 (100) 
Median survival (IQR), days 167 (45-460) 55 (22-153) 12 (3-36) 
Tissue diagnosis attempted 2023 (81) 295 (60) 43 (35) 
Tissue diagnosis achieved 1887 (76) 245 (50) 33 (27) 
Number of procedures    
0 469 (19) 195 (40) 79 (65) 
1 1608 (65) 250 (51) 34 (28) 
2 346 (14) 39 (8) 6 (5) 
3 or more 70 (3) 6 (1) 3 (2) 
1st procedure    
Bronchoscopy 875 (35) 123 (25) 15 (12) 
EBUS 386 (16) 43 (9) 4 (3) 
CT biopsy 260 (10) 23 (5) 4 (3) 
US biopsy node 186 (7) 24 (5) 1 (1) 
Pleural aspirate 133 (5) 39 (8) 13 (11) 
Tissue type    
NSCLC 1515 (61) 190 (39) 27 (21) 
SCLC 371 (15) 55 (11) 7 (6) 
Unknown 606 (24) 245 (50) 89 (73) 
Treatment    
 Any active treatment 1102 (67) 151 (31) 6 (5% 
Surgery 287 (12) 0 0 
Radical XRT +/- chemotherapy 252 (10) 8 (2) 0 
Chemotherapy +/- Palliative XRT NSCLC 287 (12) 5 (1) 0 
Chemotherapy +/- Palliative XRT SCLC 276 (11) 20 (4) 0 
Palliative XRT 541 (22) 118 (24) 6 (5) 
 Best supportive care 827 (33) 339 (69) 116 (95) 
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 Table 3: Logistic regression of likelihood of attempting a tissue diagnosis in patients 
of performance status 3 and 4 
 
 
 
*Reference category Stage 1 
**Scottish index of multiple deprivation 
 
 
Table 4: Cox regression of survival in patients of performance status 3 and 4 
 
 
Variables excluded from model on univariate testing: socioeconomic status and tissue 
diagnosis achieved 
*Reference category Stage 1  
 
 
 Odds 
ratio 
95% confidence interval p-value 
Age 0.92 0.90-0.94 <0.001 
Male sex 0.79 0.55-1.13 0.20 
Performance status 4 0.31 0.20-0-49 <0.001 
Stage*    <0.001 
1 1   
2 0.54 0.28-1.04 0.06 
3 0.26 0.11-0.59 0.001 
4 1.79 1.14-2.80 0.01 
Socioeconomic status**   0.99 
 Hazard 
ratio 
95% confidence interval p-value 
Age 0.99 0.98-1.0 0.006 
Male sex 1.17 0.98-1.37 0.07 
Performance status 4 2.09 1.70-2.57 <0.001 
Stage*     
1 1   
2 1.07 0.66-1.73 0.78 
3 1.65 1.15-2.36 0.01 
4 2.96 2.11-4.17 <0.001 
Treatment needing tissue 0.63 0.44-0.92 0.01 
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 Table 5: Comparison of patients who underwent treatment for lung cancer that 
required tissue diagnosis with those who did not have treatment requiring tissue 
diagnosis 
 
 Had treatment requiring 
tissue 
Did not have treatment 
requiring tissue 
n 33 563 
Male sex 26% 52% 
Age 70 73 
Stage   
1 5 (15) 40 (7) 
2 1 (3) 31 (5) 
3 8 (24) 123 (21) 
4 19 (57) 385 (67) 
Performance status   
3 7) 93) 
4 0) 100) 
Tissue type   
No tissue diagnosis* 3 (9) 331 (57) 
SCLC  9 (64) 41 (7) 
NSCLC 21 (27) 207 36) 
   
Median survival (IQR), days 75 (45-369) 39 (14-106) 
Treatment   
Radical XRT 8 (24)  
Chemotherapy for SCLC 20 (61)  
Chemotherapy for NSCLC 5 (15)  
 
All data presented as n(%) except median survival (interquartile range) 
 
*3 patients received radical radiotherapy based on radiological appearances alone. 
SCLC: small cell lung cancer; NSCLC: non small cell lung cancer; XRT: 
radiotherapy. 
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10. Figure legends 
 
Figure 1: Treatment administered in patients of poor performance status 
 
Figure 2: Panel A Survival curves of patients with poor performance status by 
whether or not a tissue diagnosis was established Panel B Survival curves of patients 
with poor performance status in whom treatment requiring a tissue diagnosis was and 
was not administered   
 


